Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0114 | 0.5 | 0.5 |
Leishmania major | oxidoreductase-like protein | 0.0114 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0114 | 0.5 | 0.5 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0114 | 0.5 | 0.5 |
Mycobacterium ulcerans | short chain dehydrogenase | 0.0114 | 0.5 | 0.5 |
Mycobacterium ulcerans | short-chain type dehydrogenase/reductase | 0.0114 | 0.5 | 0.5 |
Mycobacterium ulcerans | 3-alpha-hydroxysteroid dehydrogenase | 0.0114 | 0.5 | 0.5 |
Toxoplasma gondii | 2,4-dienoyl CoA reductase 2, peroxisomal family protein | 0.0114 | 0.5 | 0.5 |
Mycobacterium ulcerans | short-chain type dehydrogenase/reductase | 0.0114 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0114 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | > 300 uM | Cytotoxicity against human HeLa cells expressing CD4 and CCR5 assessed as cell viability after 6 days by XTT assay | ChEMBL. | 23206859 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.